SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
-2.58%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$210M
AUM Growth
+$210M
(+5.7%)
Cap. Flow
+$16.7M
Cap. Flow
% of AUM
7.99%
Top 10 Holdings %
Top 10 Hldgs %
36.19%
Holding
76
New
21
Increased
12
Reduced
17
Closed
15
Top Buys
| 1 |
iShares Biotechnology ETF
IBB
|
$9.29M |
| 2 |
Bristol-Myers Squibb
BMY
|
$7.31M |
| 3 |
Elevance Health
ELV
|
$7.19M |
| 4 |
Gilead Sciences
GILD
|
$5.73M |
| 5 |
McKesson
MCK
|
$4.92M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
$7.8M |
| 2 |
Amgen
AMGN
|
$7.51M |
| 3 |
Medtronic
MDT
|
$5.62M |
| 4 |
GSK
GSK
|
$5.39M |
| 5 |
Eli Lilly
LLY
|
$5.15M |
Sector Composition
| 1 | Healthcare | 83.15% |
| 2 | Financials | 3.55% |
| 3 | Industrials | 1.31% |
| 4 | Consumer Staples | 0.98% |
| 5 | Energy | 0.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares Biotechnology ETF
IBB
$5.6B
| $9.29M | 4.43% |
+35,000
| New | +$9.29M |
|
2
Humana
HUM
$36.5B
| $7.83M | 3.74% |
38,382
-5,000
| -12% | -$1.02M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $7.81M | 3.73% |
67,500
-5,000
| -7% | -$579K |
|
|
AET
4
DELISTED
Aetna Inc
AET
| $7.44M | 3.55% |
60,000
+20,000
| +50% | +$2.48M |
|
5
AstraZeneca
AZN
$248B
| $7.38M | 3.52% |
270,000
+70,000
| +35% | +$1.91M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $7.34M | 3.5% |
60,000
| – | – |
|
|
7
Bristol-Myers Squibb
BMY
$96B
| $7.31M | 3.49% |
+125,000
| New | +$7.31M |
|
8
UnitedHealth
UNH
$281B
| $7.2M | 3.44% |
45,000
+10,000
| +29% | +$1.6M |
|
|
9
Elevance Health
ELV
$71.8B
| $7.19M | 3.43% |
+50,000
| New | +$7.19M |
|
10
Centene
CNC
$14.3B
| $7.06M | 3.37% |
125,000
+35,000
| +39% | +$1.98M |
|
11
Merck
MRK
$210B
| $6.77M | 3.23% |
115,000
-5,000
| -4% | -$294K |
|
12
Cigna
CI
$80.3B
| $6.67M | 3.18% |
50,010
+5,010
| +11% | +$668K |
|
13
Regeneron Pharmaceuticals
REGN
$61.5B
| $6.42M | 3.06% |
17,500
+3,500
| +25% | +$1.28M |
|
|
14
Gilead Sciences
GILD
$140B
| $5.73M | 2.73% |
+80,000
| New | +$5.73M |
|
15
Biogen
BIIB
$19.4B
| $5.67M | 2.71% |
20,000
| – | – |
|
16
Incyte
INCY
$16.5B
| $5.52M | 2.63% |
55,000
-5,000
| -8% | -$501K |
|
|
WCG
17
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.48M | 2.62% |
40,000
-5,000
| -11% | -$685K |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.97M | 2.37% |
60,000
-10,000
| -14% | -$828K |
|
|
19
McKesson
MCK
$85.4B
| $4.92M | 2.35% |
+35,000
| New | +$4.92M |
|
20
Molina Healthcare
MOH
$9.8B
| $4.88M | 2.33% |
90,000
+10,000
| +13% | +$543K |
|
|
BCR
21
DELISTED
CR Bard Inc.
BCR
| $4.49M | 2.14% |
+20,000
| New | +$4.49M |
|
22
Becton Dickinson
BDX
$55.3B
| $4.14M | 1.97% |
25,000
+2,500
| +11% | +$414K |
|
23
Johnson & Johnson
JNJ
$427B
| $4.03M | 1.92% |
35,000
-25,000
| -42% | -$2.88M |
|
24
Cencora
COR
$56.5B
| $3.91M | 1.87% |
+50,000
| New | +$3.91M |
|
25
Boston Scientific
BSX
$156B
| $3.79M | 1.81% |
175,000
-25,000
| -13% | -$541K |
|